A Novel Intramuscular Bivalent Norovirus Virus-Like Particle Vaccine Candidate—Reactogenicity, Safety, and Immunogenicity in a Phase 1 Trial in Healthy Adults

The Roles of Clostridium difficile and Norovirus Among Gastroenteritis-Associated Deaths in the United States, 1999–2007

(2012) Aron J. Hall et al.   CLINICAL INFECTIOUS DISEASES

Predicting Susceptibility to Norovirus GII.4 by Use of a Challenge Model Involving Humans

(2012) R. Frenck et al.   JOURNAL OF INFECTIOUS DISEASES

Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations

(2012) Gabriel I. Parra et al.   VACCINE

Serological Responses to Experimental Norwalk Virus Infection Measured Using a Quantitative Duplex Time-Resolved Fluorescence Immunoassay

(2011) Owen Kavanagh et al.   Clinical and Vaccine Immunology

Increasing Rates of Gastroenteritis Hospital Discharges in US Adults and the Contribution of Norovirus, 1996–2007

(2011) Ben A. Lopman et al.   CLINICAL INFECTIOUS DISEASES

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule

(2011) Barbara Romanowski et al.   Human vaccines & immunotherapeutics

Norovirus Vaccine against Experimental Human Norwalk Virus Illness

(2011) Robert L. Atmar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Serological Correlate of Protection against Norovirus‐Induced Gastroenteritis

(2010) Amanda Reeck et al.   JOURNAL OF INFECTIOUS DISEASES

Adjuvanted Intranasal Norwalk Virus‐Like Particle Vaccine Elicits Antibodies and Antibody‐Secreting Cells That Express Homing Receptors for Mucosal and Peripheral Lymphoid Tissues

(2010) Samer S. El‐Kamary et al.   JOURNAL OF INFECTIOUS DISEASES